rajasekharkakarla
☆    

India,
2018-07-24 11:05
(2190 d 16:54 ago)

Posting: # 19087
Views: 2,730
 

 Reference trademark issue [Regulatives / Guidelines]

Dear All,

I prepared protocol for Mesalamine delayed-release tablets 1.2 gm for USFDA submission, i written reference name as Lialda™ (mesalamine) delayed release tablets 1.2 gm with trademark TM and the protocol was approved by EC. But as per COA it is mentioned as Lialda®, there is change in trademark. kindly suggest whether i need to go with ammendment/not.

Regards'
Kakarla
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2018-07-24 18:57
(2190 d 09:02 ago)

@ rajasekharkakarla
Posting: # 19093
Views: 2,503
 

 Note to File

Hi Kakarla,

IMHO, no big deal.
stands for an unregistered trademark, as opposed to an registered trademark ®. Will not affect the safety of the subjects in the study. Hence, no substantial amendment (EC and regulatory approval) is required. Maybe just a “Note to File” is enough. If you want to be on the safe side, go for an administrative amendment.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
rajasekharkakarla
☆    

India,
2018-07-30 15:37
(2184 d 12:21 ago)

@ Helmut
Posting: # 19115
Views: 2,604
 

 Note to File

Dear Sir,

Thank you for your clarification.

Thanks and Regards,
Kakarla Rajasekhar
UA Flag
Activity
 Admin contact
23,113 posts in 4,858 threads, 1,644 registered users;
53 visitors (0 registered, 53 guests [including 14 identified bots]).
Forum time: 03:59 CEST (Europe/Vienna)

You can’t really say “similar” if it’s the same again you want.
“Similar” means something different.    Anthony Burgess

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5